sab-142
Generic: human anti-thymocyte globulin
sab-142: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| SAB BIOTHERAPEUTICS, INC. (SABS) | Phase 2 |
FDA Decisions
FDA_MeetingFDA provided clear, constructive, and actionable guidance leading to alignment on the design and advancement of the Phase 2b SAFEGUARD study.(SABS)
Frequently asked questions
Who is developing sab-142?
sab-142 is being developed by SAB BIOTHERAPEUTICS, INC..
What is sab-142's latest FDA decision?
The most recent tracked FDA decision for sab-142 is FDA_Meeting for FDA provided clear, constructive, and actionable guidance leading to alignment on the design and advancement of the Phase 2b SAFEGUARD study., dated May 29, 2025.
Get deeper analysis on sab-142
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis